-
Tytuł:
-
Current role of carbamazepine and oxcarbazepine in the management of epilepsy.
-
Autorzy:
-
Beydoun A; Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
DuPont S; Epilepsy Unit and Rehabilitation Unit, Hôpital de la Pitié-Salpêtrière, AP-HP, Centre de recherche de l'Institut du cerveau et de la moelle épinière (ICM), UMPC-UMR 7225 CNRS-UMRS 975 Inserm, Paris, France; Université Paris Sorbonne, Paris, France.
Zhou D; Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Matta M; Novartis Pharma Services, Dubaï, United Arab Emirates.
Nagire V; Novartis Pharma, Mumbai, India.
Lagae L; Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium. Electronic address: .
-
Źródło:
-
Seizure [Seizure] 2020 Dec; Vol. 83, pp. 251-263. Date of Electronic Publication: 2020 Dec 14.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : Elsevier
Original Publication: London : Baillière Tindall, c1992-
-
MeSH Terms:
-
Anticonvulsants/*therapeutic use
Carbamazepine/*therapeutic use
Epilepsy/*drug therapy
Oxcarbazepine/*therapeutic use
Epilepsy, Generalized/drug therapy ; Humans ; Topiramate/therapeutic use
-
Contributed Indexing:
-
Keywords: Carbamazepine; Epilepsy guidelines; Focal onset seizures; Oxcarbazepine; Real-world effectiveness; Therapeutic strategy
-
Substance Nomenclature:
-
0 (Anticonvulsants)
0H73WJJ391 (Topiramate)
33CM23913M (Carbamazepine)
VZI5B1W380 (Oxcarbazepine)
-
Entry Date(s):
-
Date Created: 20201218 Date Completed: 20210104 Latest Revision: 20210104
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.seizure.2020.10.018
-
PMID:
-
33334546
-
Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide. Despite a dramatic increase in treatment options over the past 30 years, it still ranks fourth in the world's disease burden. There are now close to 30 antiepileptic drugs (AEDs), with more than two thirds introduced to the market after carbamazepine (CBZ) and one third after its derivative, oxcarbazepine (OXC). Following the introduction of these newer AEDs, the role of CBZ and OXC in the therapeutic armamentarium for seizure control and effective epilepsy management needs to be reviewed. The main guidelines list both CBZ and OXC as first-line options or second-line alternatives for the treatment of focal-onset epilepsy and primary generalized tonic-clonic seizures. While evidence suggests that overall AEDs have similar efficacy, some newer AEDs may be better tolerated than CBZ. In line with this, there have been changes in treatment patterns, with many variations across different countries. However, CBZ remains among the two or three most prescribed drugs for focal epilepsy in many countries, and is widely used across Europe, Africa, South America, and Asia, where it represents a good compromise between cost, availability, and effectiveness. OXC is among the first-choice options for the initial treatment of focal-onset seizures in several countries, including the US and China, where the oral suspension is commonly prescribed. This review provides guidance on the optimal use of these two drugs in clinical practice, including in children, the elderly, and in pregnancy.
(Copyright © 2020. Published by Elsevier Ltd.)
